Related Experiment Videos
Japanese clinical trials with Takeda acellular pertussis vaccine
H Kuno-Sakai1, M Kimura, K Ozaki
1Department of Pediatrics, School of Medicine, Totaki University, Kanagawa, Japan.
Insights
Japanese infants 3-8 months old showed strong immune responses to Takeda acellular pertussis vaccine, comparable to 2-year-olds. General reactions were similar, with fewer local reactions observed in infants.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Pertussis remains a significant public health concern globally.
- Acellular pertussis vaccines are widely used for infant immunization.
- Understanding vaccine efficacy and safety in young infants is crucial for public health strategies.
Purpose of the Study:
- To evaluate the immunogenicity and safety of the Takeda acellular pertussis vaccine in infants aged 3 to 8 months.
- To compare the immune response and reaction profile in infants with that of older children.
Main Methods:
- Japanese clinical trials were conducted.
- Infants aged 3 to 8 months received the Takeda acellular pertussis vaccine.
- Antibody levels (anti-PT and anti-FHA) and general/local reactions were assessed and compared to 2-year-old children.
Main Results:
- Infants demonstrated sufficient immune responses, with anti-pertussis toxin (anti-PT) and anti-filamentous hemagglutinin (anti-FHA) antibody levels comparable to those in 2-year-old children.
- No substantial differences in general systemic reactions were observed between the infant and 2-year-old groups.
- Infants experienced fewer local reactions at the vaccination site compared to the older children.
Conclusions:
- The Takeda acellular pertussis vaccine is immunogenic and well-tolerated in infants aged 3 to 8 months.
- The vaccine elicits comparable antibody responses in young infants and older children.
- These findings support the use of this acellular pertussis vaccine in early infant immunization schedules.
Abstract:
Japanese clinical trials with Takeda acellular pertussis vaccine revealed that infants 3 to 8 months of age reacted sufficiently to the vaccine: anti-PT ant-FHA levels after vaccination were as high as those observed with 2 year old children. No substantial difference in general reactions was noted between infants and 2 year old children. Less local reactions were noted in infants.